All In Biotech

Drug Trial Radar · NCT03156114

This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.

An Open Label, Phase I Dose-finding Study of BI 754111 in Combination With BI 754091 in Patients With Advanced Solid Cancers Followed by Expansion Cohorts at the Selected Dose of the Combination in Patients With Non-small Cell Lung Cancer and Other Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

172

Actual

Start

Jun 13, 2017

Primary completion

Mar 9, 2023

Study completion Jun 6, 2023

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
May 17, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study in adults with advanced solid tumors including non-small cell lung cancer. The study tests the combination of two medicines called BI 754111 and BI 754091 that may help the immune system to fight the cancer. Such medicines are called immune checkpoint inhibitors. The study has two parts. In the first part, doctors want to find out the highest dose of 2 medicines that people with solid tumors can tolerate. This dose is then used for the second part of the study. In the second part, the combination of the two medicines is tested in patients with non-small cell lung cancer and other types of solid cancer. These patients had gotten treatment with anti-PD-1 or anti-PD-L1 medicines but their tumors have come back. The doctors check whether the combination of BI 754111 and BI 754091 makes tumors shrink. Both medicines are given as an infusion into the vein every 3 weeks. If there is benefit for the patients and if they can tolerate it, the treatment is given for maximum of 1 year. During the entire study doctors will regularly check the health of the patients.

Conditions

  • Neoplasms
  • Carcinoma, Non-Small-Cell Lung

Interventions

  • EzabenlimabDrug

    240 mg ezabenlimab given as an intravenous infusion on day 1 of 21-day cycles (q3w)

  • BI 754111Drug

    Different dosages of BI 754111 given as an intravenous infusion on day 1 of 21-day cycles (q3w).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation: Maximum-tolerated Dose (MTD) of the BI 754111 Plus Ezabenlimab CombinationTime frame: First treatment cycle, the first 21 days following the start of trial medication.
  2. Dose Escalation: Number of Patients Experiencing DLTs During the Combination MTD Evaluation PeriodTime frame: First treatment cycle, the first 21 days following the start of trial medication.
  3. Dose Expansion: Number of Patients With Objective Response (OR) - Confirmed Complete Response (CR) and Partial Response (PR)Time frame: From the date of the first administration of trial treatment until the date of the last administration of trial treatment + 30 days (residual effect period), up to 818 days.

Locations

15 sites in 5 countries. Site status is shown where the registry gives one.

  • University of Miami

    Miami, Florida

  • Florida Cancer Specialists

    Sarasota, Florida

  • John Theurer Cancer Center

    Hackensack, New Jersey

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • Tennessee Oncology, PLLC

    Nashville, Tennessee

  • Froedtert and The Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Cross Cancer Institute (University of Alberta)

    Edmonton, Alberta, Canada

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • BioVirtus Research Site Sp. z o.o.

    Józefów, Poland

  • Oncology Center-Maria Sklodowska-Curie Institute

    Warsaw, Poland

  • Hospital Universitari Dexeus

    Barcelona, Spain

  • Hospital General Universitario Gregorio Marañón

    Madrid, Spain

  • Hospital Universitario HM Sanchinarro

    Madrid, Spain

  • Hospital Politècnic La Fe

    Valencia, Spain

  • Sarah Cannon Research Institute

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.